A Food and Drug Administration Advisory Panel recently voted 20-12 to keep the diabetes drug Avandia on the market even though data suggests it raises the risk of a heart attack. John Buse, MD, a PI extender at the NC Translational and Clinical Sciences Institute and director of the UNC Diabetes Care, was one of the first physicians to raise concerns about the drug (and was labeled a “renegade” by executives at drug maker GlaxoSmithKline for doing so). Here he answers questions on the latest decision by the FDA and what it could mean for the treatment of the millions of Americans living with diabetes.